- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | Cellyan Biotechnology Co., Ltd - F-1, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| CELLYAN BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 18.03. | Cellyan Biotechnology Co., Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.01. | Cellyan Biotechnology receives Nasdaq minimum bid price deficiency notice | 1 | Investing.com | ||
| 16.01. | Cellyan Biotechnology receives Nasdaq bid price deficiency notice | 1 | Seeking Alpha | ||
| 16.01. | Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency | 261 | GlobeNewswire (Europe) | HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply... ► Artikel lesen | |
| 16.01. | Cellyan Biotechnology Co., Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.12.25 | Hong Kong Pharma Digital Technology Holdings Limited Announced Results of 2025 Annual Meeting of Stockholders | 1.649 | GlobeNewswire (Europe) | HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 49,810 | -1,76 % | Märkte am Morgen: Bayer, Deutsche Bank, SAP, Delivery Hero, Easyjet, ASML | Der DAX hat in der vergangenen Woche abgeliefert. Ein Plus von 4,5 Prozent bedeutet die beste Handelswoche seit April 2025. Vor allem an den letzten Tagen blies der DAX zur Rekordjagd, stellte eine... ► Artikel lesen | |
| GSK | 22,870 | -0,44 % | COPD-Forschung: AstraZeneca greift zu: Milliardenchance mit neuem Lungenmedikament? | © Foto: CFOTO - picture alliance / CFOTOAstraZeneca sichert sich die Exklusivrechte außerhalb Chinas an einem COPD-Wirkstoff. Der Deal kann auf bis zu 1,9 Milliarden US-Dollar anwachsen.AstraZeneca... ► Artikel lesen | |
| CANOPY GROWTH | 0,859 | +0,44 % | Is Canopy Growth Stock Finally Worth Buying After Losing 99% of Its Value? | ||
| EYEPOINT | 12,500 | -3,85 % | EyePoint, Inc.: EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer | WATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,028 | -0,96 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| COMPASS PATHWAYS | 11,700 | -2,50 % | Compass Pathfinder Limited: Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile | New 6-month data supports COMP360's potential to establish a new standard of care in TRD Data from positive COMP006 Phase 3 trial demonstrates durable benefit through at least 6 months... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 11,350 | +1,34 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 8,645 | +1,89 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer | NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage company focused on developing promising new therapies... ► Artikel lesen | |
| DARE BIOSCIENCE | 2,025 | +0,25 % | Daré Bioscience, Inc.: Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event | ||
| CITIUS PHARMACEUTICALS | 0,583 | 0,00 % | Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | $5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR®
Citius Pharma raised $5 million in a registered direct offering; Citius... ► Artikel lesen | |
| ELEDON PHARMACEUTICALS | 3,480 | -2,25 % | Natera, Eledon Partner On Kidney Transplant Monitoring Test For Phase 3 Trial; Stock Up | WASHINGTON (dpa-AFX) - Cell-free DNA testing company Natera, Inc. (NTRA) and Eledon Pharmaceuticals, Inc. (ELDN) announced on Thursday that they have entered into a partnership to use Natera's... ► Artikel lesen | |
| CENTESSA PHARMACEUTICALS | 34,600 | 0,00 % | Centessa Pharmaceuticals plc - 15-12G, Securities registration termination | ||
| EXICURE | 1,270 | -9,93 % | Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement | WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the "Company") today announced that it received a notification letter from the Listing Qualifications Department of... ► Artikel lesen | |
| CHINA SXT PHARMACEUTICALS | 2,600 | +1,96 % | China SXT Pharmaceuticals, Inc. - 6-K, Report of foreign issuer | ||
| COSMOS HEALTH | 0,283 | +10,48 % | Cosmos Health Inc.: Cosmos Health Launches Subscription Model | Subscription model already launched with NOOR Collagen in the United StatesEarly data shows a repeat purchase rate above 60% at high margins in excess of 50%Model is designed to drive stronger loyalty... ► Artikel lesen |
Das Unternehmen CELLYAN BIOTECHNOLOGY CO LTD kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,450 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLYAN BIOTECHNOLOGY CO LTD finden Sie auf Wallstreet Online.